Iraq Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iraq Healthcare Wire.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on December 9, 2025

$Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia$

December 9, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire

December 9, 2025

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

GlobeNewswire

December 9, 2025

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

GlobeNewswire

December 9, 2025

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

GlobeNewswire

December 9, 2025

Pow.Bio and Bühler join forces to advance next-generation precision fermentation

GlobeNewswire

December 9, 2025

Terns Announces Proposed Public Offering

GlobeNewswire

December 9, 2025

Global Separation Systems Market for Commercial Biotechnology Projected to Reach $45.1 Billion by 2030

GlobeNewswire

December 9, 2025

Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836

GlobeNewswire

December 9, 2025

Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders

GlobeNewswire

December 9, 2025

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

GlobeNewswire

December 9, 2025

Relation announces further $26 million investment

GlobeNewswire

December 9, 2025

Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH

GlobeNewswire

December 9, 2025

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

GlobeNewswire

December 9, 2025

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur

GlobeNewswire

December 9, 2025

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

GlobeNewswire

December 9, 2025

Chiropractic Expert Dr. Kevin D. Trembush of Morgantown Shares What to Expect During Your First Chiropractic Visit in HelloNation

GlobeNewswire

December 9, 2025

2025 Assessment Finds U.S. Cities Are Taking Action to Advance Health Policy; 11 Improve Overall Medal Status

GlobeNewswire

December 9, 2025

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

GlobeNewswire

December 9, 2025

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

GlobeNewswire

December 9, 2025

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

GlobeNewswire